A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Phase 1 Terminated
3 enrolled
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Terminated
16 enrolled
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Phase 2 Terminated
5 enrolled 11 charts
HeartPhone Cancer Survivors Trial 2019
Phase 1/2 Terminated
2 enrolled 6 charts
topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Phase 1 Terminated
28 enrolled 19 charts
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
27 enrolled
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Phase 2 Terminated
30 enrolled
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Phase 2 Terminated
51 enrolled 8 charts
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
Phase 2 Terminated
2 enrolled 10 charts
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Phase 1/2 Terminated
93 enrolled 27 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 Terminated
12 enrolled
YASU Research Registry: For Young Adults With Cancer
Terminated
192 enrolled
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Phase 2 Terminated
4 enrolled 7 charts
REGALIA
Phase 2 Terminated
9 enrolled
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Phase 1 Terminated
56 enrolled 24 charts
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
25 enrolled 8 charts
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Phase NA Terminated
2,117 enrolled 6 charts
PROACT
Phase 2 Terminated
49 enrolled 12 charts
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Phase 1/2 Terminated
67 enrolled
A Long-term Follow-up Study of Patients Who Received VOR33
Terminated
10 enrolled
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
Phase 1/2 Terminated
38 enrolled
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Phase 1 Terminated
101 enrolled 54 charts
Phase l/II Study of Ruxolitinib for Acute Leukemia
Phase 1/2 Terminated
27 enrolled 6 charts
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
Phase 4 Terminated
10 enrolled 12 charts
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Phase 1 Terminated
10 enrolled